Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 7 min read

Thymosin Alpha-1: sourcing, documentation and price

Thymosin Alpha-1 (Tα1) is a thymus-derived immunomodulatory peptide supplied for laboratory research. This page covers its identifiers, the receptor work it appears in, the study record, and how research-supply documenta

peptides-pro Editorial

Thymosin Alpha-1 — also written thymosin alpha-1, Tα1, and thymalfasin — is a synthetic 28-amino-acid peptide corresponding to the N-terminal fragment of prothymosin alpha, and is classified as an immunomodulatory peptide hormone of thymic origin. The evidence block used for this page does not supply a sequence string, molecular formula or molecular weight, so none are stated here; researchers requiring those values should obtain them from the certificate of analysis accompanying the specific lot. The work described below centres on the peptide's engagement of the hypocretin (orexin) receptor HCRTR1 in neurons, alongside its better-characterised activity on T-cell and antigen-presenting-cell populations [1][3].

Thymosin Alpha-1 is catalogued as Thymosin Alpha-1, 5 mg, supplied for laboratory research use only. It is not a therapeutic product, and nothing on this page is a dosing instruction or a clinical claim.

Research Studies

Thymosin Alpha-1 and HCRTR1-mediated suppression of neuronal necroptosis

Work on the thymus–CNS axis reported that Tα1 acts as a non-canonical ligand for the hypocretin (orexin) receptor 1 (HCRTR1), a classical neuropeptide receptor expressed on neurons. Engagement of HCRTR1 in that model shielded neurons from cell death by suppressing the activity of Receptor-Interacting Protein Kinase 3 (RIPK3), described in the paper as a central executioner of necroptosis. The authors framed the finding as a direct neuroprotective axis linking the thymus to the central nervous system [1].

This is a mechanistic finding. It identifies a receptor interaction and an intracellular effector, and it does not establish an effect in humans.

Thymosin Alpha-1 and immune-related adverse events from checkpoint inhibition

A case report described a patient with nasopharyngeal carcinoma who developed multisystem immune-related adverse events (irAEs) after treatment with the PD-1 inhibitor sintilimab in combination with thymosin alpha-1. The presentation included high fever, rash, interstitial pulmonary edema and multiple organ failure. The authors analysed the treatment course and discussed risks and management strategies for combining immune checkpoint inhibitors with immunomodulators, concluding that clinical vigilance is needed against possible immune overactivation triggered by the combination [2].

A registered trial has been set up to explore whether Tα-1 could serve as a therapeutic option for the treatment of irAEs secondary to immune checkpoint inhibitors, on the basis that Tα-1 has shown clinical benefit in patients whose immune function is severely compromised or ineffective [4].

Thymosin Alpha-1 and immunosenescence in aging populations

Aging is characterised by immune decline driven mainly by thymic involution, the age-related shrinkage of the thymus, which reduces T-cell production, sustains chronic inflammation and increases susceptibility to age-related disease. Tα1 is described in that literature as a thymus-produced peptide hormone with immunomodulatory, anti-inflammatory and antioxidant properties, acting by stimulating T-cell differentiation, enhancing thymic output, and modulating dendritic cell and macrophage activity. Preclinical and clinical studies cited in that review report that Tα1 can improve vaccine response in elderly subjects and mitigate immunosenescence [3].

The population named in those findings is elderly humans, with supporting preclinical work; the review also discusses a hybrid drug construct, Refnot, which is a distinct agent and not the peptide supplied here [3].

Thymosin Alpha-1 and dendritic cell chaperoning of a TLR7 ligand

Chemotherapy induces cancer cell apoptosis and release of apoptotic bodies that are poorly immunogenic or immunosuppressive, which is a barrier to coadministered or second-line immunotherapy. In that study, circulating levels of Tα-1 were found to be reduced, and the peptide was reported to restore chemotherapy-induced antitumor immunity by chaperoning a microRNA ligand of TLR7 in dendritic cells [9].

Thymosin Alpha-1 in unresectable hepatocellular carcinoma

A retrospective study set out to validate the efficacy and safety of thymosin α-1 combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma, in patients treated at the People's Hospital of Guangxi Zhuang Autonomous Region from January 20 onward [10]. The population is patients with unresectable hepatocellular carcinoma receiving a three-agent regimen; the design is retrospective, so the findings are associative rather than causal.

Thymosin Alpha-1 in thyroid and endocrine-immune contexts

A review of peptide therapies in thyroid health notes that thyroid disorders, particularly autoimmune conditions such as Hashimoto's thyroiditis, are frequently associated with persistent systemic symptoms despite biochemical normalisation on standard hormone replacement, which has prompted investigation into adjunctive strategies targeting immune, metabolic and neuroendocrine pathways [11]. Tα1 appears in that discussion as one such adjunctive candidate; the review is a survey of emerging applications rather than a controlled efficacy result.

Thymosin Alpha-1 in recurrent implantation failure

A registered clinical trial is evaluating the safety and efficacy of Tα1 as an adjunctive immunomodulatory therapy in women with unexplained recurrent implantation failure (RIF) undergoing IVF/ICSI cycles [7]. The population is women with unexplained RIF; the study is registered, and no outcome data are reported in the record.

Thymosin Alpha-1 combined with checkpoint blockade in esophageal cancer

A prospective, single-arm, multicentre study conducted in China is enrolling patients with pathologically or cytologically confirmed resectable esophageal squamous cell carcinoma to explore the efficacy and safety of adebrelimab combined with thymalfasin and chemotherapy as neoadjuvant therapy. The design comprises a screening period of no more than 21 days from informed consent to first study drug administration, a treatment period covering neoadjuvant therapy and surgery, and a follow-up period comprising safety and survival follow-up [6].

Thymosin Alpha-1 in combination regimens: comparison of registered protocols

The table below compares the registered and reported combination settings in which Tα1 appears in the evidence block. It compares protocols, not outcomes.

SettingPopulationCombination partnersDesignSource
irAE managementPatients with irAEs secondary to ICIsTα-1 as therapeutic optionRegistered trial[4]
Esophageal squamous cell carcinomaResectable ESCC, ChinaAdebrelimab + chemotherapyProspective, single-arm, multicentre[6]
Recurrent implantation failureWomen with unexplained RIF, IVF/ICSIAdjunctive immunomodulationRegistered trial[7]
Unresectable hepatocellular carcinomaPatients at one centre in GuangxiLenvatinib + sintilimabRetrospective[10]
Nasopharyngeal carcinoma (case)Single patientSintilimabCase report[2]

Thymosin Alpha-1 in acute aortic dissection and soft tissue sarcoma protocols

Two further registered protocols place Tα1-adjacent immunotherapy within broader regimens. In acute aortic dissection, an AI-assisted immunoinflammatory subtyping system is being tested in a prospective multicentre randomised controlled trial of 300 patients, randomised to subtyping-based precision therapy or empirical strategies, on the rationale that immunoinflammatory response drives lesion progression and current perioperative anti-inflammatory therapy is largely empirical [5]. In soft tissue sarcoma, a prospective, multicentre, open-label, single-arm phase II study is evaluating spatially fractionated radiotherapy combined with a strategy that includes Toripalimab and recombinant human granulocyte-macrophage colony-stimulating factor [8]. Neither record reports Tα1-specific outcomes.

Sourcing and documentation

Research-supply material is documented by lot. The identifiers a laboratory typically needs — sequence, formula, molecular weight, purity and counter-ion — are lot-specific and are not reproduced on this page because the evidence block does not provide them. Where a study above reports a receptor interaction or an effector protein, the corresponding in-house verification is a matter for the receiving laboratory's own assays.

Price

Price for research-supply peptides is set per catalogue unit rather than per milligram of active, and is published on the product listing rather than in this article. The listing for the 5 mg presentation is the authoritative source for current price and pack size.

If you are reading this for personal health reasons

This material is sold for laboratory research only, and we do not provide dosing or medical guidance of any kind. Anyone considering a compound for themselves should speak to a licensed clinician. The studies cited here were conducted in defined patient or preclinical populations under controlled conditions and do not transfer to self-administration.

Sources

WhatsApp